• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


Prices delayed by at least 15 minutes | Print

Xenon Pharmaceuticals (XENE)

Common Shares
Sell: $35|Buy: $40.41|Change: 0.62 (1.56%)

This share can be held in a Dealing accountISALifetime ISAJISASIPP

Company profile

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

Address

200-3650 Gilmore Way
Burnaby
BC
CAN
V5G 4W8

Telephone

+1 604 4843300

Website

https://www.xenon-pharma.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Xenon Pharmaceuticals Inc First Quarter Earnings Conference Call for 20252025-05-09T16:30:00
Xenon Pharmaceuticals Inc First Quarter Earnings Results for 20252025-05-09T00:00:00
Xenon Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20242025-02-28T16:30:00
Xenon Pharmaceuticals Inc Fourth Quarter Earnings Results for 20242025-02-28T00:00:00
Xenon Pharmaceuticals Inc Annual Report for 20242025-02-28T00:00:00
Xenon Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20242024-11-08T16:30:00
Xenon Pharmaceuticals Inc Third Quarter Earnings Results for 20242024-11-08T00:00:00
Xenon Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20242024-08-09T16:30:00
Xenon Pharmaceuticals Inc Second Quarter Earnings Results for 20242024-08-09T00:00:00
Xenon Pharmaceuticals Inc Annual General Meeting for 20242024-05-31T11:30:00
BofA Securities Health Care Conference 20242024-05-15T06:40:00
RBC Capital Markets Global Healthcare Conference 20242024-05-14T03:35:00
Xenon Pharmaceuticals Inc First Quarter Earnings Conference Call for 20242024-05-09T16:30:00
Xenon Pharmaceuticals Inc First Quarter Earnings Result for 20242024-05-09T00:00:00

Previous key dates

NameKey Date
Xenon Pharmaceuticals Inc Annual General Meeting for 20242024-05-31T11:30:00
BofA Securities Health Care Conference 20242024-05-15T06:40:00
RBC Capital Markets Global Healthcare Conference 20242024-05-14T03:35:00
Xenon Pharmaceuticals Inc First Quarter Earnings Conference Call for 20242024-05-09T16:30:00
Xenon Pharmaceuticals Inc First Quarter Earnings Result for 20242024-05-09T00:00:00
Xenon Pharmaceuticals Inc 2024 Bloom Burton & Co. Healthcare Investor Conference2024-04-16T09:30:00
Xenon Pharmaceuticals 23rd Annual Needham (Virtual) Healthcare Conference2024-04-11T15:00:00
Xenon Pharmaceuticals Inc Stifel Virtual CNS Days 20242024-03-19T12:30:00
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 20242024-03-11T11:20:00
Xenon Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20232024-02-29T16:30:00
Xenon Pharmaceuticals Inc Fourth Quarter Earnings Result for 20232024-02-29T00:00:00
Xenon Pharmaceuticals Inc Annual Report for 20232024-02-29T00:00:00
Xenon Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20232023-11-08T16:30:00
Xenon Pharmaceuticals Inc Third Quarter Earnings Result for 20232023-11-08T00:00:00
Xenon Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20232023-08-09T16:30:00
Xenon Pharmaceuticals Inc Second Quarter Earnings Result for 20232023-08-09T00:00:00
Xenon Pharmaceuticals Inc Annual General Meeting for 20232023-06-01T11:30:00
Xenon Pharmaceuticals Inc First Quarter Earnings Conference Call for 20232023-05-09T16:30:00
Xenon Pharmaceuticals Inc First Quarter Earnings Result for 20232023-05-09T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.